Cero Therapeutics Holdings Inc. recently amended its securities purchase agreement, adding new institutional investors to issue and sell shares of its Series D convertible preferred stock. On June 25, 2025, the company completed an Additional Closing, selling 2,315 shares for approximately $1,852,000. Previously, on June 5, 2025, the company sold an additional 938 shares for about $750,400. The transactions were conducted under exemptions from the Securities Act for private placements to accredited investors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.